This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

EYLEA® (aflibercept) 8 mg

Innovative Mechanism of Action

Mechanism of Action

EYLEA 8mg provides 4x the molar dose of aflibercept compared with EYLEA 2mg, resulting in an effective concentration for longer in the eye^*

What is a Higher Molar Dose?

Theoretically, a higher Molar dose is able to suppress disease activity longer than Eylea 2mg thereby resulting in sustained disease control, in the eye.^*

1:1 BINDING

Aflibercept traps VEGF and PIGF ligand dimers, forming inert 1:1 complexes

LONG-LASTING ANTI-VEGF ACTIVITY

PK models estimate that aflibercept 8 mg exhibits an unexpected 34% slower ocular clearance than aflibercept 2 mg; slower ocular clearance facilitates longer VEGF suppression

^{*Based on mathematical modelling and the clinical relevance is unknown}

Prescribing information for EYLEA® (aflibercept) can be found here:

EYLEA® Prescribing Information

Dosing

Discover proactive dosing in nAMD and DME

Safety

Explore the safety profile of EYLEA 8mg

Abbreviations

DME

^{, diabetic macular oedema;}^Fc^{, fragment crystallisable;}^IgG^{, immunoglobulin G;}^nAMD^{, neovascular (wet) age-related macular degeneration;}^PK^{, pharmacokinetic;}^PIGF^{, placental growth factor;}^VEGF^{, vascular endothelial growth factor;}^VEGFR^{, vascular endothelial growth factor receptor.}

PP-EYL_8mg-IE-0158-1 | January 2026

References

1
EYLEA® 114.3 mg/mL Summary of Product Characteristics.
2
Veritti D, et al. Pharmaceutics 2023;15:1416.
3
Papadopoulos N, et al. Angiogenesis 2012;15:171–185
4
Kanda A, et al. Sci Rep 2015;5:17946.
5
Amadio M, et al. Pharmacol Res 2016;103:253–269.
6
Fauser S & Muether PS. Br J Ophthalmol 2016;100:1494–1498.
7
EMA. EYLEA EPAR assessment report 2014. Available at: https://www.ema.europa.eu/en/documents/variation-report/eylea-h-c-2392-ii-0013-epar-assessment-report-variation_en.pdf. Accessed: December 2025.
8
Holash J, et al. Proc Natl Acad Sci USA 2002;9:11393–11398.
9
EYLEA (aflibercept) – European public assessment report. Available at: https://www.ema.europa.eu/en/documents/overview/eylea-epar-medicine-overview_en.pdf. Accessed: December 2025.